PTC takes a chance on Sangamo's Fabry disease gene therapy

PTC Therapeutics has acquired Sangamo's gene therapy for Fabry disease, viewing it as a high-risk, high-reward opportunity that may surpass current treatments pending regulatory approval.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.